<DOC>
	<DOC>NCT00619307</DOC>
	<brief_summary>To assess patient satisfaction with respect to the incidence of flu-like symptoms (FLS) in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44 mcg three-times-weekly) to the new formulation of Rebif (RNF) while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurence of flu-like symptoms.</brief_summary>
	<brief_title>Transition to Rebif New Formulation</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Subject with relapsing forms of Multiple Sclerosis (MS) Expanded disability status scale (EDSS) score &lt; 5.5 at study entry Subjects who have been administering Rebif 44 mcg three times a week for at least 6 months prior to study enrolment Subject currently using Rebiject II and who will use their own Rebiject II for the Rebif New Formulation injections Subject is between 18 and 60 years old inclusive Female subjects must be neither pregnant nor breastfeeding and must lack childbearing potential, as defined by either: postmenopausal or surgically sterile, or use a highly effective method of contraception. Subject is willing to follow study procedures Subject is willing and must not present any contraindication to taking ibuprofen during 4 weeks of the study Subject has given written informed consent Secondary Progressive Multiple Sclerosis without superimposed attacks Use of any other injectible medications during the week prior to the screening period, during the screening or treatment periods Subject receiving MS therapy in addition (i.e. combination therapy) to Rebif within 3 months prior to study enrolment or at any time during study protocol History of any chronic pain syndrome Subjects that use any investigational drug or experimental procedure within 12 weeks of visit Subject received corticosteroids or adrenocorticotrophic hormone (ACTH) within 30 days of visit 1 Subject with flulike symptoms (FLS) associated with any cause (i.e. no current flu and no FLS related to Interferon in the week prior to baseline) Subject has abnormal liver function, defined by a total bilirubin &gt; 1.5 times the upper limit of normal, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 times the upper limit of the normal values. Subject has inadequate bone marrow reserve, defined as a total white blood cell count &lt; 3.0 x 109/L, platelet count &lt; 75 x 109/L, haemoglobin &lt; 100 g/L. Subject suffers from an active autoimmune disease other than MS Subject suffers from major medical or psychiatric illness Subject has seizures history or is currently experiencing seizures not adequately controlled by antiepileptics Subject is pregnant or attempting to conceive Visual or physical impairment that precludes completion of diaries and questionnaires by himself/herself Contraindication to ibuprofen:known hypersensitivity to the active ingredient ibuprofen Known hypersensitivity to nonsteroidal antiinflammatory drugs which can lead to asthmatic attacks, gastric and/or intestinal ulcers, gastrointestinal bleeding, cerebrovascular bleeding or other active bleeding, severe hepatic dysfunction, severe kidney dysfunction, severe cardiac insufficiency, or systemic lupus erythematosus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>